|

Investigator's choice of chemotherapy Clinical Trials

4 actively recruiting trials across 3 locations

▼ -1 trial since June 2026

Also known as: GemNabP, ICC, gemcitabine, mFOLFIRINOX, paclitaxel +2 more

Pipeline

Phase 3: 4

Top Sponsors

  • Incyte Corporation2
  • K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc1
  • Fudan University1

Indications

  • Cancer4
  • Ovarian Cancer2
  • Mutation1
  • Metastatic Breast Cancer1
  • Solid Tumors1

Other1 trial

Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
Phase 3

Birmingham, Alabama1 trial

A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma

Investigative Site US058

Phase 3

Anchorage, Alaska1 trial

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

Alaska Womens Cancer Care Akwcc

Phase 3

Phoenix, Arizona1 trial

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

Site 0107

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.